|
|
|
| Study on Correlation between Coagulation Indexes and Homocysteine β2 Microglobulin and Occurrence of End-Stage Renal Disease in Patients with Hypertensive Nephropathy |
| BAI Ruoyue, LI Qin |
| The Affiliated Hospital of Yan'an University, Shaanxi Yan'an 716000, China |
|
|
|
|
Abstract Objective: To analyze the correlation between coagulation indexes and homocysteine (Hcy), β2-microglobulin (β2-MG) and occurrence of end-stage renal disease (ESRD) in patients with hypertensive nephropathy (HN). Methods: A total of 138 patients with HN in the hospital from August 2019 to August 2021 were selected as the study group. According to the occurrence of ESRD after 3 years of follow-up, the above patients were divided into ESRD group (n=26) and non-ESRD group (n=112). In addition, 102 hypertensive patients without nephropathy who received examination in the hospital during the same period were included in the control group. The levels of coagulation indexes [D-dimer (D-D), fibrinogen (Fib), fibrinogen degradation product (FDP)], Hcy and β2-MG were measured among all study subjects. The correlation between D-D, Fib and FDP levels and Hcy and β2-MG levels in hypertensive nephropathy patients was analyzed by Pearson correlation, and the correlation between D-D, Fib and FDP levels and the occurrence of end-stage nephropathy in hypertensive nephropathy patients was analyzed by Logistic regression. Results: The levels of serum D-D, Fib, FDP, Hcy and β2-MG in the study group were higher than those in the control group (P<0.05). Serum D-D, Fib, FDP, Hcy and β2-MG levels were higher in the ESRD group than those in the non-ESRD group (P<0.05). Correlation analysis indicated that serum D-D, Fib and FDP levels were positively correlated with Hcy and β2-MG levels in patients with HN (r=0.771, 0.795; 0.568, 0.619; 0.545,0.591, P<0.05). The levels of D-D, Fib and FDP in hypertensive nephropathy patients were independent risk factors for end-stage nephropathy (P<0.05). Conclusion: The levels of D-D, Fib and FDP in hypertensive nephropathy patients were positively correlated with the levels of Hcy, β2-MG and end-stage nephropathy.
|
|
|
|
|
|
[1] Peng Z,Xu Q,Hu W,et al.Review on molecular mechanism of hypertensive nephropathy[J].Curr Pharm Des,2023,29(32):2568-2578.
[2] 左君秋,余燕燕,周红霞,等.凝血指标联合血清单核细胞趋化蛋白-1对慢性肾脏病患者急性肾损伤的预测价值[J].中国血液净化,2024,23(4):277-281.
[3] Lin L,Wang C,Ren J,et al.A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension[J].Hypertens,2023,41(8):1306-1312.
[4] Xu Y,Wu J,Gao L,et al.α-Mangostin reduces hypertension in spontaneously hypertensive rats and inhibits EMT and fibrosis in Ang II-induced HK-2 cells[J].Int Med Sci,2024,21(9):1681-1688.
[5] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,中华医学会《中华全科医师杂志》编辑委员会,等.高血压基层诊疗指南(实践版·2019)[J].中华全科医师杂志,2019,18(8):723-731.
[6] Liu L,Zhou X,Yan H,et al.Symptom relief for patients with senile hypertension[J].Asian Surg,2023,46(12):6089-6090.
[7] Zhang Y,Zhang N,Zou Y,et al.Deacetylation of septin4 by SIRT2 (silent mating type information regulation 2 homolog-2) mitigates damaging of hypertensive nephropathy[J].Circ Res,2023,132(5):601-624.
[8] 张军,方利,郑小玲,等.透析模式对终末期肾病患者心血管结局影响的研究进展[J].重庆医学,2023,52(21):3314-3318.
[9] 丁瑾,传小文.瑞舒伐他汀联合缬沙坦对老年原发性高血压早期肾损伤患者肾功能及凝血功能的影响[J].血栓与止血学,2021,27(4):632-633,636.
[10] Li Y,Zhong X,Yang F.Silencing HE4 alleviates the renal fibrosis in lupus nephritis mice by regulating the C3/MMPs/prss axis[J].Naunyn Schmiedebergs Arch Pharmacol,2024,397(7):4823-4831.
[11] 贺松敏,王宝喜,江杨阳,等.终末期肾病维持性血液透析患者β2-MG、EOS水平与颈动脉粥样硬化及预后的关系[J].现代生物医学进展,2023,23(11):2178-2182.
[12] 陈晨,杨润,冯俊琦,等.成人肝移植术后急性肾损伤的发生与术后凝血功能变化的关系[J].器官移植,2022,13(2):219-224.
[13] 吴小娅,戴康伟,曾瑞颖,等.同型半胱氨酸联合β2微球蛋白对H型高血压患者肾损害的早期预测价值[J].中国卫生检验杂志,2022,32(10):1228-1231. |
|
|
|
2025, Vol. 31 
